Hostname: page-component-54dcc4c588-tfzs5 Total loading time: 0 Render date: 2025-10-06T13:44:04.604Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-acting Paliperidone in the Management of Severe Behavioral Disturbances Post-Traumatic Brain Injury: A Case Report

Published online by Cambridge University Press:  26 August 2025

A. Y. Al Ghailani ,
H. Mirza  and
S. Al Adawi
A. Y. Al Ghailani*
Affiliation:
Psychiatry, Oman Medical Speciality Board
H. Mirza
Affiliation:
Behavioural Medicine, Sultan Qaboos University Hospital, Muscat, Oman
S. Al Adawi
Affiliation:
Behavioural Medicine, Sultan Qaboos University Hospital, Muscat, Oman
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Traumatic brain injury (TBI) is a critical public health issue that often results in lasting cognitive and behavioral impairments.

These impairments include heightened risks for psychiatric disorders, such as aggression, social withdrawal, and mood instability.

Managing TBI-related behavioral symptoms can be complex, particularly in adolescent patients, where non-adherence to medication presents additional challenges.

Objectives

To evaluate the effectiveness of long-acting injectable paliperidone palmitate in managing severe behavioral disturbances following TBI in an adolescent patient with a history of non-adherence to oral antipsychotic treatments.

Methods

A case study approach was employed to detail the treatment and outcomes of a 16-year-old male who developed persistent aggressive and impulsive behaviors following a severe TBI at age 9.

The patient’s treatment history involved multiple oral antipsychotic trials, each limited by adherence issues or side effects, before transitioning to paliperidone palmitate injections.

Behavioral outcomes were monitored, and family-reported assessments of improvement were collected.

Results

Following the initiation of monthly paliperidone palmitate injections at an initial dose of 100 mg, later increased to 150 mg, the patient showed significant reductions in aggression and improved behavioral control.

Family members observed fewer aggressive outbursts and better social interactions.

Mild side effects, including weight gain and an increase in prolactin levels, were reported, but these were generally well tolerated by the patient.

Conclusions

This case demonstrates the potential benefits of long-acting injectable antipsychotics for managing behavioral dysregulation in TBI patients who struggle with medication adherence.

Paliperidone palmitate was effective in stabilizing the patient’s behavior, underscoring the need for tailored, multidisciplinary treatment plans that incorporate both pharmacological and psychosocial interventions to optimize long-term recovery in TBI-related neuropsychiatric care.

Disclosure of Interest

None Declared

Information

Type
Abstract
Information
European Psychiatry , Volume 68 , Special Issue S1: Abstracts of the 33rd European Congress of Psychiatry , April 2025 , pp. S533
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.